期刊文献+

丝氨酸/苏氨酸激酶15在甲状腺乳头状癌诊治中的意义

Expression and significance of STK15 gene in parpillary thyroid carcinoma
下载PDF
导出
摘要 目的:探讨甲状腺乳头状癌组织中丝氨酸/苏氨酸激酶15(STK15)的表达及其作用。方法:采用免疫组织化学法检测71例甲状腺乳头状癌组织及其癌旁组织和45例结节性甲状腺肿组织中STK15基因的表达。结果:71例甲状腺乳头状癌组织中STK15基因的阳性表达率均为100.0%,癌旁组织STK15阳性表达率8.45%,结节性甲状腺肿组织中STK15阳性表达率为24.4%。在甲状腺乳头状癌组织中STK15的表达具有相关性(P<0.01)。结论:STK15基因在甲状腺乳头状癌组织中均为高表达,通过检测STK15可提高甲状腺乳头状癌的诊断率,对发现具有恶性潜能的结节性甲状腺肿有重要意义。 Objective To explore the expression of serine/threonine kinase 15 (STK15) gene and its significance for papillary thyroid carcinoma. Methods SP immunohistochemical method was used to detect the expression of STK15 gene in 71 cases of papillary thyroid carcinoma and 45 cases nodular goiter tissue. Results The positive expression rates of STK15 gene in 71 cases of papillary thyroid carcinoma were 100%, and the adjacent of papillary thyroid carcinoma expressions of STK15 gene 8.5%, nodular goiter tissue of STK15 gene expression rates 24.4%. The expression of STK15 gene was positively correlated with that of STK15 gene in papillary thyroid carcinoma (P 〈 0.01). Conclusion High expression of STK15 gene is confirmed in papillary thyroid carcinoma. The detection of STK15 gene can provide valuable evidence for diagnosis of papillary thyroid carcinoma and evaluation of the malignant potential of nodular goiter.
出处 《实用医学杂志》 CAS 北大核心 2015年第5期740-742,共3页 The Journal of Practical Medicine
基金 汕头市科技局资助项目(编号:2012-165)
关键词 甲状腺肿瘤 丝氨酸/苏氨酸激酶15 诊断 治疗 Papillary Thyroid Carcinoma Serine/Threonine Kinase 15 Diagnosis Treatment
  • 相关文献

参考文献9

  • 1杨雷,王宁.甲状腺癌流行病学研究进展[J].中华预防医学杂志,2014,48(8):744-748. 被引量:126
  • 2Ferlay J, Shin HR, Bray F, et al. Cancer Incidence andMortality Worldwide: 1ARC Cancer [EB/OL].( 2010-07-01)[2012-09-13 ] .http : //globocan. iarc. fr.
  • 3Xiang J, Wu Y, Li DS, et al. New clinical features of thyroidcancer in eastern China [J]. J Vise Surg, 2010,147(5 Suppl):53-56.
  • 4Kesisova IA, Nakos KC, Tsolou A, et al. Tripolin A, a novelsmall-molecule inhibitor of aurora A kinase, reveals new regulationof HURPfs distribution on microtubules [J]. PLoS One, 2013 , 8(3):e58485.
  • 5Sen S, Zhou H, Zhang RD, et al. Amplification overexpressionof a mitotickinase gene in human bladder cancer [J]. J NatlCancer Inst, 2002,94( 17) : 1320-1329.
  • 6Lee SJ, Cimica Y, Ramachandra N, et al. Aurora A is arepressed effector target of the chromatin remodeling proteinINII/hSNF5 required for rhalxloid tumor cell survival [J].Cancer Res, 2011,71 (9) :3225-3235.
  • 7Meinhold CL, Ron E, Schonfeld SJ, et al. Nonradiation riskfactors for thyroid cancer in the US radiologic technologists study[J]. Am J Epidemiol,2010,171 (2):242-252.
  • 8杨勇,杨宏新.Aurora-A与survivin在甲状腺癌中的表达及意义[J].实用医学杂志,2011,27(23):4241-4243. 被引量:4
  • 9Kwiatkowski N. Selective aurora kinase inhibitors indentifiedusing a taxol-induced checkpoint sensitivity screen [J]. ACSChem Biol, 2012,1 (1) : 185-196.

二级参考文献66

  • 1项丞,刘伟松,贾深汕.Survivin基因在甲状腺癌中的表达及意义[J].中华医学杂志,2007,87(25):1761-1763. 被引量:8
  • 2Hu W, Kavanagh J J, Deaver M, et al. Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell ovarian cancer [J]. Oncol Res, cultures derived from human 2005,15( 1 ) :49-57.
  • 3Kamada K, Yamada Y, Hirao T, et al. Amplification/ overexpression of Aurora-A in human gastric carcinoma: potential role in differentiated type gastric carcinogenesis [J]. Oncol Rep, 2004,12(3) :593-599.
  • 4Lentini L, Amato A, Schillaci T, et al. Stimultaneous Aurora- A/STK15 overexpression and centrosome amplification induce chromosomal instability in tumour cells with a MIN phenotype [J]. BMC Cancer, 2007,7(1):212.
  • 5Comperat E, Roupret M, Conort P, et al. Aurora-A/STK15 is differentially expression in the Micropapillary Variant of Bladder Cancer [J]. Urd Int, 2009,82(3):312-317.
  • 6Jantscher F, Pirker C, Mayer C E, et al. Overexpression of Aurora-A in primary ceils interferes with S-phase entry by diminishing cyclin D1 dependent activities [J]. Mol Cancer, 2011,10:28.
  • 7Lee S J, cimica V, Ramachandra N, et al. Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival [J]. Cancer Res, 2011,71(9) :3225-3235.
  • 8Haghpanah V, Shooshtarizadeh P, Heshmat R, et al. Immunohistochemical analysis of survivin expression in thyroid follicular adenoma and carcinoma [J]. Appl Immunohistochem Mol Morphol, 2006,14(4) :422-425.
  • 9Biran A, Brownstein M, Haklai R, et al. Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy [J]. Int J Cancer, 2011,128(3) :691-701.
  • 10北京市人民政府.北京市2012年度卫生与人群健康状况报告[M].北京:人民卫生出版社,2013:45.

共引文献128

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部